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CASE REPORT
A novel swine-origin influenza A (H1N1) virus
was first identified as a causal agent of large-scale
community outbreaks of a respiratory illness 
in Mexico in April 2009.1 The World Health
Organization declared the outbreak to be a pan-
demic on June 11, 2009, and the number of 
laboratory-confirmed cases has increased rapidly.2
Although most of the confirmed cases have been
self-limited and uncomplicated febrile respiratory
illness, there have been severe infection with com-
plications or mortality as well. As of September
20, 2009, up to 318,925 laboratory-confirmed
cases of novel H1N1 infection and 3917 deaths
have been reported to WHO from 191 countries
on different continents.3 As of September 28,
2009, a total of 298 laboratory-confirmed cases
of severe influenza illness requiring hospitaliza-
tion and 18 deaths have been reported in Taiwan.4
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During the novel influenza A (H1N1) pandemic, some patients developed acute respiratory distress syn-
drome or severe cardiopulmonary failure despite the use of conventional management. Extracorporeal
membrane oxygenation (ECMO) support may successfully rescue these severely ill patients. Here, we re-
port the first case of severe novel H1N1 infection with multiorgan failure that was successfully treated with
antiviral therapy and ECMO in Taiwan. A 32-year-old man had acute onset of fever, dry cough, rhinorrhea,
and sore throat 2 days after returning from Dongguan, China. He attended Hospital A and chest radiogra-
phy revealed bilateral lung consolidation. Rapid influenza antigen testing was negative. He was intubated
2 days later due to hypoxic respiratory failure and persistent shock refractory to conventional manage-
ment. Because of compromised cardiopulmonary function, venoarterial ECMO support was started 4 days
after the onset of symptoms and he was transferred to Hospital B on July 25, 2009. As history taking found
clustering of influenza-like illness, oseltamivir was given immediately under the impression of severe in-
fluenza illness. Real-time reverse transcriptase-polymerase chain reaction of respiratory sample for novel
H1N1 virus revealed positive results. In addition, blood cultures collected at Hospital A yielded
Streptococcus pneumoniae, and β-hemolytic Streptococcus other than group A, B or D. Hospital course was
uneventful and he was discharged 26 days after transfer to Hospital B. This experience showed that ECMO
can be life-saving for severe novel H1N1 infection. [J Formos Med Assoc 2009;108(11):894–898]
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Here, we report the first case of novel H1N1 in-
fection that was successfully treated with extra-
corporeal membrane oxygenation (ECMO) in
Taiwan.
Case Report
A 32-year-old man, a previously healthy engineer,
and three companions had travelled to Dongguan,
China from July 17 to July 19, 2009. After having
returned to Taiwan for 2 days, he had acute onset
of fever, dry cough, rhinorrhea, and sore throat,
but had no nausea, vomiting, or abdominal pain.
He attended the emergency department of a
local hospital (Hospital A) on July 23, 2009 and
denied any systemic diseases or smoking.
On examination, the patient was conscious
and oriented; his body mass index was 21.7 kg/m2.
His blood pressure (BP) was 124/78 mmHg, pulse
rate was 131 beats/min, body temperature was
37.2°C, respiratory rate was 26 breaths/min, and
oxygenation saturation was 94% while he was
given an oxygen mask with 10 L/min oxygen flow.
Auscultation revealed bilateral rales and regular
heart sounds without audible murmurs. Electro-
cardiography revealed normal sinus rhythm. Chest
radiography revealed bilateral lung consolidation
(Figure 1A). Laboratory tests revealed a white
blood cell count of 5.45 × 103 cells/mm3, hemo-
globin level of 12.8 g/dL, platelet count of
212,000/mm3, creatine kinase of 918 IU/L, tro-
ponin I of 0.13 ng/mL, creatinine of 2.2 mg/dL
and blood urea nitrogen of 36 mg/dL. Liver func-
tion tests were within normal limits. Rapid in-
fluenza antigen test was negative.
The patient was intubated on the day of ad-
mission due to hypoxemic respiratory failure.
Minocycline and piperacillin/tazobactam were
given empirically. Profound shock developed on
the next day and was supported by intra-aortic
balloon pump. Transthoracic cardiac ultrasonog-
raphy revealed poor cardiac contractility with an
estimated left ventricular ejection fraction (LVEF)
of 31%. Coronary angiography showed patent
coronary arteries. Because of compromised 
cardiopulmonary function and unstable hemo-
dynamics [BP 81/41 mmHg under dopamine
17.8 μg/kg/min, dobutamine 2.8 μg/kg/min;
PaO2/FiO2 (arterial oxygen tension/inspired oxy-
gen fraction) ratio 82.8], venoarterial ECMO
support was given 4 days after the onset of symp-
toms. Then he was transferred to the intensive
care unit (ICU) of Hospital B on July 25, 2009.
On arrival, his BP was 113/70 mmHg 
under dopamine 11.17 μg/kg/min, pulse rate was
75 beats/min, body temperature was 36.6°C,
respiratory rate was 12 breaths/min, and oxygen 
saturation was 97% under mechanical ventila-
tion with 70% oxygen. Laboratory tests revealed
a white blood cell count of 5.86 × 103 cells/mm3,
hemoglobin level of 9.1 g/dL, platelet count of
98,000/mm3, creatine kinase of 343 IU/L, creati-
nine of 1.9 mg/dL and blood urea nitrogen of
45.2 mg/dL. Chest radiography showed consoli-
dation in progression (Figure 1B). Transthoracic
cardiac ultrasonography revealed dilated four
chambers, diffusely hypokinetic and an estimated
LVEF of 20–25%. As history taking had revealed
the clustering of influenza-like illness in all four
members who had traveled together to China,
the patient was reported to the Taiwan Centers
for Disease Control under the impression of 
severe influenza illness complicated with acute
respiratory distress syndrome, septic shock, and
secondary bacterial infection.
The patient was treated with oseltamivir
(75 mg twice daily) empirically in addition to
broad-spectrum antibacterial therapy (moxi-
floxacin, cefepime, and vancomycin). Real-time re-
verse transcriptase-polymerase chain reaction of
respiratory sample for novel H1N1 virus per-
formed at the laboratory of the Taiwan Centers for
Disease Control showed positive results. Two sets
of blood cultures collected at Hospital A yielded
Streptococcus pneumoniae and β-hemolytic Strepto-
coccus other than group A, B or D. Antibiotics
were reduced to moxifloxacin alone. During ICU
stay, hydrocortisone (200 mg/day) was given due
to refractory septic shock. Transvenous right ven-
tricular endomyocardial biopsy was done and
histopathology showed hypertrophy with mildly
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degenerated myocytes; some inflammatory cells
were noted in the vascular channels. Computed
tomographic scanning of the chest and abdomen
revealed bilateral lung consolidation with
ground-glass opacities and bilateral pleural effu-
sion (Figure 2), and a 2.1-cm hypervascular tumor
at the left adrenal gland. On ICU day 5 and 
day 7, dopamine was discontinued and fever
subsided, respectively. On ICU day 9 and day 10,
ECMO and intra-aortic balloon pump were re-
moved, respectively. Follow-up transthoracic 
cardiac ultrasonography revealed LVEF of 55%
and good left ventricular contractility. He was ex-
tubated on ICU day 13 (Figures 1C and 1D) and
discharged 26 days after admission to Hospital B.
Discussion
Here we reported the first case of severe novel
H1N1 infection with multiorgan failure that was
successfully treated with antimicrobial therapy,
including oseltamivir, and intensive care includ-
ing ECMO support, in Taiwan. ECMO has been
applied in infants, and less commonly in chil-
dren, with respiratory or cardiac failure.5 However,
the use of ECMO is controversial in adults.
Favorable outcomes in patients with acute respi-
ratory distress syndrome and other causes of 
severe respiratory failure have been reported.6–8
Several nonrandomized studies have also shown
that ECMO may be effective in patients with 
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Figure 1. Chest radiography shows: (A) bilateral lung consolidation 2 days after the onset of symptoms in Hospital A; 
(B) progression of pneumonia and shock refractory to conventional management 4 days after the onset of symptoms; 
(C) improved pneumonic patch on day 13 after antiviral therapy in ICU in Hospital B; (D) almost complete resolution of
bilateral consolidation on day 20 of admission.
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septic shock that is resistant to conventional
management.5
Before we applied ECMO in this patient, no
case of successful treatment of severe influenza
infection by ECMO has been reported in the 
literature. Due to the refractory cardiopulmonary
failure and the fact that the ventilator cannot
support oxygenation, ECMO was applied in this
case. From this experience, we believe that ECMO
may be helpful in some influenza cases with se-
vere cardiopulmonary failure in spite of antiviral
therapy.
During influenza pandemics, empirical antivi-
ral therapy should not be withheld from patients
with severe influenza-like illness even if the rapid
influenza test is negative. The sensitivity of rapid
antigen tests varies among commercial kits and
has been shown to be low (38.3–69.0%) in some
studies.9–11 The viral load in respiratory speci-
mens can be affected by the timing of the speci-
men collection (the highest viral load is present
in the first 3 days after disease onset), age, type of
specimen collected, and transportation as well as
storage of the specimen.9 These findings indicate
that a negative result does not rule out the possi-
bility of novel H1N1 virus infection.9–11 Our pa-
tient received oseltamivir 4 days after the onset
of symptoms, and his clinical condition gradu-
ally improved after 5 days of antiviral therapy.
Our finding is concordant with the current 
recommendation that antiviral treatment of hos-
pitalized patients with suspected influenza be
given even if it has been ≥ 48 hours after disease
onset.12
The optimal dosing and duration of treatment
are unclear. Limited data for seasonal influenza
treatment suggest that doubling the oseltamivir
dose is well-tolerated with acceptable adverse 
effects.13 Higher dosing and longer duration of
oseltamivir treatment for H5N1 avian influenza
has been suggested.14 The role of corticosteroid in
the management of severely ill patients with novel
H1N1 infection remains unclear and routine use
is not recommended.15
In conclusion, during influenza pandemics,
novel H1N1 infection should be suspected and
treated accordingly when the patient has influenza-
like illness and clustering of infection. Empirical
antiviral treatment is recommended for all hos-
pitalized patients on admission with suspected
novel H1N1 virus infection even if rapid antigen
test results are negative. Furthermore, clinical con-
dition should be monitored closely for any pos-
sible sudden deterioration. ECMO support may
be helpful in some influenza cases with severe
refractory cardiopulmonary failure despite con-
ventional management.
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